Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized Controlled Trial of Abiraterone Acetate (II) Combined with ADT Versus Abiraterone Acetate Combined with ADT in Patients with Metastatic Castration-resistant Prostate Cancer

NCT06768255 is registered in ClinicalTrials.gov with Ding-Wei Ye as lead sponsor.

NCT NCT06768255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06768255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized Controlled Trial of Abiraterone Acetate (II) Combined with ADT Versus Abiraterone Acetate Combined with ADT in Patients with Metastatic Castration-resistant Prostate Cancer
Lead sponsor
Ding-Wei Ye
Phase
Phase 3
Overall status
Not yet recruiting
Start date
January 30, 2025
Completion date
June 30, 2029
Enrollment
400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

abiraterone acetate, mcrpc (metastatic castration-resistant prostate cancer)